Incentives for antibiotics: Summary of DRIVE-AB / Slides from the 6-8 Sep 2017 ASM-ESCMID meeting

Dear All:

I wrote twice last week with materials from the 5-8 Sep ASM-ESCMID conference (EMA-FDA-NICE updates and the CARB-X + GARDP Bootcamps. But there’s more … in parallel, we last week also had the final DRIVE-AB conference in Brussels! In the absence of a Star Trek transporter it was not possible to attend both, but I did hear from others who attended and I also gave a talk at the ASM-ESCMID conference in which I summarized some of the material from the final DRIVE-AB conference.

My summary talk can be downloaded here. Highlights for your consideration would be:

  • Antibiotics are the fire extinguishers of medicine, but we currently pay for them as if we were paying the fire department on a per fire basis. As you know well, this is the fundamental economic hurdle to overcome.
  • As a path to transforming the way policymakers stimulate innovation, responsible use and global access to novel antibiotics to meet public health needs, DRIVE-AB sought solutions that were consistent with the principles of Access, Sustainable Use, and Innovation.
  • To achieve this, DRIVE-AB created 4 blocks of insight: (1) a common language for measuring things like sustainable use, (2) models to predict emergence & spread of AMR, (3) new HTA metrics for antibiotic value, and (4) incentive models.
  • The first three of these elements are the building blocks that support the fourth element, the incentive models for antibacterial R&D (see graphic below).
  • Four incentive models are recommended. Two provide Push (Grants & a Pipeline Coordinator) and two provide Pull (Market Entry Rewards and a Long-Term Continuity Model). All four of these models are important as they together drive innovation, while supporting sustainable use and access.  Push incentives alone are not sufficient
  • Note that there is pop-quiz buried in the slide deck. The answer is found at the very end of this email … try not to look too soon!
Picture

​More details + a variety of official written reports will be forthcoming from DRIVE-AB over the next few months. And of course we now have to take the big step of making a Market Entry Reward (or two or three) happen. There is nothing definitive yet in any territory, but I am aware of a number of discussions that are making strong headway. It won’t be easy, but DRIVE-AB has definitely achieved its goal of creating the required mutual understanding among a wide group of stakeholders with diverse backgrounds.

And while DRIVE-AB has been the work of many hands, I want to in particular call out the contributions of 4 individuals. First, Stephan Harbarth (University of Geneva) and Judy Hackett (AstraZeneca) did a splendid job as the academic and industry co-leads for the overall project. And Christine Årdal (Norwegian Institute of Public Health) and David Findlay (GSK) demonstrated true leadership skills as they crystallized and summarized the debates around the incentive models.

Having been there at the birth of DRIVE-AB (James Anderson of GSK and I spent many hours working with EFPIA’s Richard Bergstrom and Brendan Barnes on the basic design of the project), I am just delighted to see it all coming to fruition! I know that it times it felt like (and was like) herding cats but we all owe these four a debt of thanks for their many hours of effort.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

PS: The answer to the pop quiz is that a reasonable rule-of-thumb would be $20m/year.

Share

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on whatsapp
Share on reddit

AMR Action Fund ($1b for P2-3): Video chat with new CEO! New committed funds!

Dear All, I’ve written before about the AMR Action Fund (9 Jul 2020 newsletter): In brief, it is ~$1b pledged by over 20 leading pharmaceutical companies to support the Phase 2-3 studies needed to bring 2-4 new antibiotics to approval by 2030 Stated differently, the AMR Action Fund provides Push incentives for Phase 2-3 to complement the Push Incentives

UK Antibiotic Subscription Pilot: Updates from a webinar

Dear All (and with thanks to Kevin Outterson for co-authoring), We’ve written and talked before from various perspectives about the groundbreaking UK NHS England-, NHS Improvement-, and NICE-sponsored antibiotic subscription pilot project: 10 Feb 2021: Fabulous 5-minute video explainer on the economics of antibiotics by Andrew Jack of Financial Times Superb discussions of Push/Pull, the role

Brilliant 5-minute video explainer of the AMR problem!

 Dear All, Andrew Jack of the Financial Times (FT) has produced a superb 5-minute video explainer of the AMR challenge! Featuring cameos from Kevin Outterson (CARB-X), Christine Ardal (Norwegian Institute of Public Health), and Manica Balasegaram (GARDP), the video deftly illustrates the economic challenge, the way that delinked Netflix-like models provide a solution, and the

Job with global impact: Director, CIDRAP Antimicrobial Stewardship Program

Dear All, Launched in 2016, the Antimicrobial Stewardship Program (ASP) at the Center for Infectious Disease Research and Policy (CIDRAP) of the University of Minnesota works to provide support globally to the the infectious disease community via such diverse activities as ASP-oriented podcasts, webinars, journal clubs, and other resources. CIDRAP itself is directed by the

Scroll to Top